Galectin-3 is a glycan-binding protein that mediates cellcell and/or cell-extracellular matrix (ECM) interactions. Although galectin-3 is implicated in the progression of various types of cancers, the mechanisms by which galectin-3 enhances metastasis remain unclear. In order to elucidate the role of galectin-3 in the complex multistage process of cancer metastasis, we examined galectin-3 and galectin-3-binding site expression in a series of 82 spontaneous canine mammary tumors (CMT) and two CMT cell lines. Benign CMT tumors exhibited strong nuclear/cytoplasmic galectin-3 immunostaining, whereas malignant CMT tumors and metastases exhibited dramatically decreased galectin-3 expression with the majority of the immunostaining confined to the cytoplasm. Interestingly, intravascular tumor cells overexpressed galectin-3 regardless of their location. CMT-U27 xenografts displayed the same pattern of galectin-3 expression found in spontaneous malignant CMT. In parallel with the downregulation of galectin-3, malignant CMT displayed an overall loss of galectin-3-binding sites in the ECM and focal expression of galectin-3-binding sites mainly detected in intravascular tumor cells and endothelium. Furthermore, loss of galectin-3-binding sites was correlated with the downregulation of GLT25D1, a β (1-O) galactosyltransferase that modifies collagen, and upregulation of stromal galectin-1. Finally, GLT25D1 mRNA expression was strikingly downregulated in malignant CMT-U27 compared with the benign cell line, and its expression was further decreased in a galectin-3 knockdown CMT-U27 cell line. We therefore hypothesized that the loss of galectin-3-binding sites in the ECM in conjunction with the overexpression of galectin-3 in specific tumor cell subpopulations are crucial events for the development of mammary tumor metastases.
Introduction
Metastasis is a major event associated with malignancies. This complex process initiates when cancer cells lose the expression of receptors responsible for homotypic and heterotypic cell adhesion and cell-extracellular matrix (ECM) interaction, escape from the primary tumor, and enter the vasculature (Chambers et al. 2002) . Once inside the vessels, however, the ability of invading tumor cells to engage into new heterotypic and homotypic adhesive interactions is a crucial step for their arrest within microcirculation, extravasation, and establishment in distant organs or tissues (Orr and Wang 2001) . Therefore, the balance between these contradictory pro-and anti-adhesive forces dictates the malignant potential of the neoplastic cell and constitutes a key for understanding the mechanisms underlying the metastatic process. It is well known that these reversible steps of homotypic and heterotypic cell-cell and cell-ECM adhesion are mediated in part by specific interactions between tumor cell-surface glycan-binding proteins and their ligands presented on other cells and/or within the tumor microenvironment (Nangia-Makker et al. 2008) .
Galectin-3 is one of the most studied members of the galectin family of glycan-binding proteins, which has been implicated in tumor progression and metastasis by promoting cell-cell (Inohara et al. 1996) and cell-ECM adhesion (Ochieng et al. 1999) , angiogenesis (Nangia-Makker et al. 2000) , cell proliferation (Honjo et al. 2001) , and by antagonizing tumor cell apoptosis (Yoshii et al. 2002) . Galectin-3 and its glycosylated ligands have been shown to play several roles closely associated to the early steps of the metastatic process. Firstly, galectin-3 is a chemoattractant to endothelial cells and stimulates neovascularization in vivo, therefore contributing to tumor angiogenesis and providing an escape route by which cells can leave the primary tumor and enter into vessels (NangiaMakker et al. 2000; Chambers et al. 2002) . Moreover, galec-tin-3 mediates homotypic (between tumor cells) and heterotypic (between tumor cells and endothelium) tumor cell adhesion (Inohara et al. 1996) . Also, by inducing homotypic aggregation and protecting circulating cells from anoikis, galectin-3 plays a role in the survival of tumor cells until arrival and establishment at distant metastatic sites (Kim et al. 1999) . Consistent with its role in tumor progression, the levels of galectin-3 expression are elevated in a variety of primary tumors (Liu and Rabinovich 2005) . However, it does not seem to be an unequivocal observation since galectin-3 increases and decreases have been reported during malignant progression of several cancers. Downregulation of galectin-3 is observed in prostate (Ellerhorst et al. 1999; Pacis et al. 2000) , ovarian (van den Brûle et al. 1994) , colon (Lotz et al. 1993) , head and neck squamous cell carcinoma (Choufani et al. 1999) , and breast cancers (Castronovo et al. 1996) . On the one hand, higher levels of galectin-3 could favor metastasis by inducing tumor cell aggregation inside tumor vasculature; on the other hand, it could increase cell-cell and cell-ECM adhesive interactions at the primary tumors, thus disfavoring the separation of individual cancer cells and metastatic dissemination. Although the ability of galectin-3 in promoting cell-ECM interactions has been used to reinforce its role in the establishment of distant metastasis in a target organ stroma (Nangia-Makker et al. 2008) , there is a lack of information on how such galectin-3-enhanced cell-ECM adhesion correlates with the escape of tumor cells from the primary tumors. These contradictory observations indicate that the precise role of galectin-3 in tumor progression and metastasis remains to be further explained.
In this study, we report that the progression of malignant canine mammary tumors (CMT) is associated with downregulation of galectin-3 and galectin-binding sites in the tumor stroma. Interestingly, in malignant CMT, galectin-3 and galectin-3-binding sites are more prominent in invading intravascular tumor cells at both the primary tumors and their respective metastases. Based on our results, we propose a model to reconcile the apparent conflicting adhesive and anti-adhesive properties of galectin-3 and suggest that altered stroma glycosylation and the occupancy of galectin-3-binding sites by endogenous galectins are critical players in the process of tumor metastasis.
Results
Galectin-3 is downregulated during the process of malignant transformation of canine mammary glands Galectin-3 downregulation has been associated with progression of various human cancers including breast (Castronovo et al. 1996) . In order to better understand how the acquisition of an invasive and metastatic phenotype is related to galectin-3 expression, we examined the expression of this protein in 82 spontaneous CMT samples. Malignant CMT (41 cases) and benign CMT (41 cases) were classified according to the histological types, grades, and mode of growth (Table 1) and to the histological types (Table 2) , respectively. The majority of benign CMT (approximately 55%) presented galectin-3 staining in more than 75% of tumor cells. In striking contrast, there were no malignant CMT with more than 75% stained cells, and most malignant tumors presented galectin-3 expression in less than 50% of tumor cells (90.2%) (Figure 1) . Therefore, we found a significant (P < 0.05) downregulation of galectin-3 expression in malignant when compared with benign CMT.
Galectin-3 is highly expressed by invasive tumor cell subpopulations in both primary and metastatic CMT Even though there was a dramatic decrease in galectin-3 expression in the primary malignant CMT, it was still expressed in a few cells at specific locations. Interestingly, galectin-3 was always strongly expressed in tumor cell emboli (Figure 2A and B) and in the vicinity of necrotic areas ( Figure 2C ). Surprisingly, in all well-established metastatic lesions, there was galectin-3 staining only in tumor cells surrounding necrotic areas, a pattern resembling that observed in the primary malignant CMT ( Figure 2D ). Nevertheless, whenever intravascular tumor cells were available for observation in metastatic lesions, it was possible to verify an intense galectin-3 staining ( Figure 2E and F). In order to check the differentiation status of galectin-3-positive tumor cells, we verified the expression of E-cadherin and beta-catenin, which are two crucial molecules for intercellular adhesion and maintenance of epithelial architecture (Nollet et al. 1999) . Interestingly, overexpression of galectin-3 was not associated with loss of membrane expression of Ecadherin since it was possible to find both E-cadherin-negative ( Figure 2G ) and E-cadherin-positive tumor emboli ( Figure 2H ) in the same tumor section. However, β-catenin expression was always found at the contact sites between intravascular tumor cells ( Figure 2I ). Altogether, these results indicate that overexpression of galectin-3 is a characteristic of potential metastatic tumor cells in malignant CMT and does not appear to be related to their differentiation status.
Cytoplasmic staining for galectin-3 is associated with increased aggressiveness in CMT Since cytoplasmic expression of galectin-3 has often been associated with tumor resistance to apoptosis and enhanced malignancy (Lotz et al. 1993; Califice et al. 2004 ), we compared galectin-3 intracellular staining pattern between benign and malignant CMT. Regarding subcellular distribution, benign CMT predominantly presented a nuclear and cytoplasmic staining (90.2% of the cases), whereas most of the malignant CMT (85.3%) showed predominantly a cytoplasmic pattern of galectin-3 expression (Figure 3 ). There was a decrease in nuclear 1343 . Galectin-3 nuclear staining is decreased in malignant CMT. Galectin-3 immunohistochemical staining was classified according to its localization expression pattern in nuc (for nuclear expression only; nuc/cyt, for both nuclear and cytoplasmic expression) and cyt (for cytoplasmic expression only). Most benign CMT presented nuclear/cytoplasmic galectin-3 expression pattern (90.2% of the cases), whereas the majority of malignant CMT presented only a cytoplasmic galectin-3 expression pattern (85.3%). *Asterisks indicate significant differences (P < 0.05) by Pearson chi-square test.
expression of galectin-3 in malignant CMT when compared with benign CMT, which proved to be statistically significant (P < 0.05). These findings point to an association of a cytoplasmic pattern of galectin-3 to malignancy in CMT.
Cytoplasmic staining for galectin-3 is associated with aggressiveness in malignant CMT cell lines In order to further address the role of galectin-3 in tumor metastasis, we took the advantage of using two CMT cell lines as a model. First, we compared the subcellular distribution of galectin-3 in benign CMA07 (which does not form tumors) and highly metastatic CMT-U27 cell lines. Similar levels of galectin-3 expression were found in CMT-U27 and CMA07 cell lines in vitro in both mRNA and protein analyses (data not shown). However, at the intracellular level, galectin-3 was expressed both in the nucleus and in the cytoplasm of the benign CMA07 cell line ( Figure 4A ), while a cytoplasmic expression pattern only was observed in the malignant CMT-U27 cell line ( Figure 4B ). Benign CMA07 showed similar levels of galectin-3 surface expression, while displaying increased expression levels of galectin-3-binding sites ( Figure 4C ) when compared with malignant CMT-U27 ( Figure 4D ). These findings suggest that galectin-3 pattern distribution in malignant CMT-U27 cells may account for the high invasive capacity of this cell line.
CMT-U27 xenografts display the same pattern of galectin-3 expression found in both primary and metastatic lesions of CMT Next, we injected the highly metastatic CMT-U27 cell line into the mammary fat pad of female nude mice and analyzed galectin-3 expression in primary tumors and metastatic lesions. Surprisingly, although CMT-U27 cells expressed galectin-3 in vitro, xenografted tumors displayed significant loss of galectin-3 expression. In two out of five primary tumors, galectin-3-positive tumor cells were less than 25%, whereas in three out of five primary tumors, galectin-3-positive tumor cells were less than 10%. In primary tumors, cells staining for galectin-3 were specifically located in necrotic regions ( Figure 5A ) and tumor emboli, as previously seen in malignant CMT ( Figure 5B ). Likewise, metastatic lesions displayed galectin-3 expression in less than 25% of the cells, mainly in those surrounding necrotic areas in five out of six lesions ( Figure 5C ) and inside tumor vessels ( Figure 5D ). These results corroborate our findings in spontaneous malignant CMT (Figures 2 and 3 ) and underscore the role of cytoplasmic and cell-surface galectin-3 expression in metastatic dissemination. Downregulation of galectin-3-binding sites in the ECM parallels the malignant transformation of canine mammary glands During the metastatic process, tumor cells need first to lose cellular adhesion, increase their motility, and migrate through the ECM (Chambers et al. 2002) . It has been suggested that galectin-3 may facilitate cancer metastasis by promoting cell-cell (homo-and heterotypic) and cell-ECM interactions through crosslinking of glycans present on other cells and ECM, respectively (Inohara et al. 1996; Ochieng et al. 1999) . Therefore, we analyzed galectin-3-binding sites in 20 benign and 20 malignant CMT, using human galectin-3 fused to alkaline phosphatase (Gal3/AP) as a probe. Surprisingly, there was a statistically significant decrease in galectin-3-binding sites in the ECM of malignant tissue when compared with the normal adjacent glands ( Figure 6A ). In most benign lesions (≈65%), the ECM presented strong expression of galectin-3-binding sites ( Figure 6B, a) . However, in the majority of malignant CMT (≈ 85%), there was a weak expression of galectin-3-binding sites in the ECM ( Figure 6B, b) . Similar results were obtained in human normal tumor-adjacent mammary glands ( Figure 6B , c) in comparison with carcinoma lesions themselves ( Figure 6B, d) , which corroborates the findings in malignant CMT. These results suggest that the coordinated decrease of galectin-3-binding sites in the ECM may account for the loss of mediated cell-ECM adhesion in the tumor microenvironment.
Galectin-3-binding sites expression is a marker of invading tumor cells in CMT Nevertheless, in malignant CMT, intravascular tumor cells and tumor vasculature strongly expressed galectin-3-binding sites ( Figure 6C, a) . Galectin-3-binding sites were also observed on the surface of moderately differentiated tumors (16 out of 20 cases) in less than 25% of tumor cells ( Figure 6C, b) . Inhibition by lactose indicated an involvement of the carbohydrate recognition domain in the binding of Gal3/AP to tissues ( Figure 6D ). These results suggest that galectin-3-binding site expression in tumor emboli and endothelial cells may propitiate galectin-3-mediated cell-cell interactions, thus facilitating metastatic spread.
Galectin-3-binding site occupancy and stromal glycosylation are partially altered in CMT In order to assess whether or not a decrease in galectin-3-binding sites is due to differential ECM glycosylation in CMT, first we used two biotinylated plant lectins: (1) Erythrina crista-galli lectin (ECA), which specifically binds β1,4 galactose and (2) Peanut lectin (PNA) , which binds terminal galactose specially to Galβ1,3GlcNAc. In normal adjacent mammary tissue, both ECA ( Figure 7A ) and PNA ( Figure 7B ) bound to matrix glycoproteins in tissue stroma and gland mucus secretion in addition to the apical border of luminal cells. In contrast, in malignant CMT, there was a striking decrease in ECA-and PNA-binding sites in the ECM ( Figure 7C and D, respectively). Since the presence of endogenous galectins in the ECM, including cleaved galectin-3 (not recognized by the mAb M3/38), could be impairing the binding of the Gal3/AP probe, we evaluated the expression of both galectin-3 and galectin-1 by using affinity-purified polyclonal antibodies. However, in our model we did not observe expressive presence of galectin-3 in the ECM even when using a polyclonal antibody ( Figure 7E ). On the other hand, galectin-1 was overexpressed in malignant CMT, mainly found in the nucleus and cytoplasm of tumor cells and scattered throughout the tumor stroma ( Figure 7F ). Finally, as collagen is a major component of the ECM and in order to verify if a defect in the collagen glycosylation could account for the decrease in galectin-3-binding sites, we assessed the mRNA expression level of GLT25D1, an enzyme essential to collagen galactosylation (Schegg et al. 2009 ). In normal mammary glands, there was amplification of GLT25D1, with slightly higher levels than in benign CMT ( Figure 7G ). However, GLT25D1 mRNA expression decreased considerably in malignant CMT when compared with benign CMT ( Figure 7G ). In fact, from four malignant CMT analyzed, there was amplification in only one, while in benign CMT there was amplification of GLT25D1 in all four studied cases. All tissue samples displayed similar expression levels of endogenous control gene (data not shown). Altogether, these results suggest that galectin-1 overexpression and downregulation of GLT25D1 mRNA expression in malignant CMT may account, at least in part, for the loss of galectin-3 binding sites in these tumors.
Galectin-3 may play a role in GLT25D1 expression level in CMT cell lines In order to verify if there was any relationship between galectin-3 and GLT25D1 expression levels, we checked the enzyme mRNA levels in both benign and malignant CMT cell lines, which display differential distribution pattern of galectin-3 (Figure 4 ). Corroborating our findings in CMT (Figure 7G ), the malignant CMT-U27 cell line displayed lower levels of GLT25D1 mRNA expression (~30-fold reduction) when compared with benign CMA07 cell line ( Figure 8A ). We further investigated the involvement of galectin-3 in the regulation of GLT25D1 expression levels by performing shRNA-mediated galectin-3 knockdown in the malignant cell line and evaluating its effects on GLT25D1 expression levels. Short hairpin RNA was directed to galectin-3, and a corresponding scrambled control was used (Friedrichs et al. 2007 ). After infection and selection, over 75% galectin-3 inhibition was reached in the malignant (CMT-U27) cell line ( Figure 8B ). Galectin-3 knockdown caused a further 50% decrease in GLT25D1 mRNA levels ( Figure 8C ), as compared with the scrambled infected cells. These results imply that the downregulation of galectin-3 may be at least partially responsible for the decreased GLT25D1 mRNA expression levels found in malignant CMT. The photomicrographs depict specific lectin-binding sites staining, using biotin-labeled Erythrina crista-galli lectin (ECA) and peanut lectin (PNA), with hematoxylin counterstain. Most normal adjacent mammary glands presented expression of ECA (A, ×20 magnification) and PNA-binding sites (B, ×20). In the great majority of malignant CMT, there was a weaker ECM expression of ECA-and PNA-binding sites (C and D, ×40). (E, F) The photomicrographs depict galectin-3 (E, × 40) and galectin-1 (F, ×40) expression with hematoxylin counterstain in malignant CMT. Using a polyclonal antibody against galectin-1 and -3, it was possible to observe the virtual absence of galectin-3 in the ECM in contrast to the strong staining for galectin-1. (G) RNA extracted from normal mammary gland and benign and malignant CMT samples were converted to cDNA and analyzed by real-time polymerase chain reaction (PCR) for the expression of GLT25D1. Enzyme mRNA expression level was considerably decreased in malignant CMT when compared with normal tissue and benign lesions. cDNA contents were normalized on the basis of predetermined levels of 18S. Data are representative of the 10 studied cases.
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Discussion
Spontaneous canine malignant mammary tumors share many similarities with human breast cancer, including prognostic factors (de Matos et al. 2006) , tumor markers (de Matos et al. 2007 ) and the metastatic dissemination process (Paoloni and Khanna 2008) . However, the incidence of CMT is three times higher than that of human breast cancer, and the time course of the disease is shorter, often less than 2 years (Sorenmo 2003) . This allowed us to collect and analyze primary and metastatic tumors from the same dogs, which would be far too complicated to carry out in humans. Therefore, besides being considered as excellent models for imaging and immunotherapy studies of human breast cancer, spontaneous CMT may also be of use to improve our knowledge about the initial steps of the metastatic process (Paoloni and Khanna 2008) . In this study, we used spontaneous benign and malignant CMT to investigate the role of galectin-3 in the metastatic process and demonstrated that: (1) overall galectin-3 expression is downregulated in malignant CMT but upregulated in intravascular tumor emboli; (2) cytoplasm expression pattern of galectin-3 correlates with CMT progression and CMT cell line aggressiveness; (3) both intravasated tumor cells and tumor endothelium express galectin-3-binding sites; (4) galectin-3-binding sites are decreased in the ECM of malignant CMT and correlate with lower expression of collagen-glycosylating enzyme GLT25D1 and with higher expression of galectin-1; (5) malignant CMT-U27 cell line displays much lower mRNA levels of GLT25D1 than benign cell line, and these levels are even further reduced upon galectin-3 knockdown.
Although galectin-3 has been implicated in the progression of various types of cancer, contradictory observations support the notion that galectin-3 can exert tumor-suppressive effects in certain scenarios. Indeed, decreased expression of galectin-3 was associated to poorer prognosis in several human cancers (Lotz et al. 1993; van den Brûle et al. 1994; Choufani et al. 1999; Ellerhorst et al. 1999; Pacis et al. 2000) , including breast cancer (Castronovo et al. 1996) . A decreased expression of galectin-3 in malignant CMT was previously described by Choi et al (2004) . However, to the best of our knowledge, this is the first study that clearly demonstrates intense expression of galectin-3 in intravascular tumor cells. Several reports showed that galectin-3 behaves as an adhesion molecule, mediating both homotypic and heterotypic cell adhesion (Ochieng et al. 2004) . Therefore, decreased galectin-3 expression would lead to reduced adhesiveness between tumor cells and facilitate cancer cell invasion. On the other hand, decreased galectin-3 expression would disfavor heterotypic aggregation between tumor cells and endothelial cells, impairing intravasation and intravascular tumor cell arrest. Since the great majority of invading tumor cells expresses galectin-3 in malignant CMT, at least three different scenarios can be envisaged: (1) only tumors cells exposed to stress conditions (e.g., hypoxia) regain galectin-3 expression and intravasate; (2) only tumor cells that do not reduce galectin-3 expression migrate and intravasate into blood vessels; and (3) infiltrating immune cells may increase migratory capacity of tumor cells by secreting galectin-3. The first scenario is supported by the fact that galectin-3 is overexpressed around necrotic (hypoxic) areas in CMT, as in human brain tumors (Neder et al. 2004) . It has been shown that in patients with advanced breast cancer and prostate cancer (Racila et al. 1998) , most of the circulating cancer cells were apoptotic (Swartz et al. 1999) , which gives support to a passive mechanism of invasion (Bockhorn et al. 2007 ). The second scenario could be explained by the acquisition of a migratory phenotype by galectin-3-expressing tumor cells. Indeed, an active mechanism of invasion, by which there is an accumulation of mutations that favor migration, has also been suggested as a result of epithelial-mesenchymal transition (EMT) (Thiery et al. 2009 ). However, since a hallmark of EMT is the loss of E-cadherin expression (Perl et al. 1998) , our results do not support the assumption that the all intravascular tumor cells found in CMT have undergone EMT. The third scenario is based on the fact that stromal cells are believed to affect the migratory behavior of tumor cells (Liotta and Kohn 2001) . Interestingly, a recent report (Wyckoff et al. 2007 ) demonstrated that perivascular macrophages interact with tumor cells and are directly involved in the intravasation step in mammary tumors. In malig- Fig. 8 . GLT25D1 mRNA expression levels in CMT cell lines correlate with both galectin-3 subcellular distribution pattern and galectin-3 expression level. RNA was extracted from benign and malignant CMT cell lines, converted to cDNA, and analyzed by real-time PCR for GLT25D1 expression. (A) Benign CMA07 cell line (nuclear and cytoplasmic galectin-3) showed GLT25D1 mRNA expression levels about 30-fold higher than those found in Malignant CMT-U27 cell line (cytoplasmic galectin-3). (B) Galectin-3 knockdown using short hairpin RNA resulted in over 75% of galectin-3 inhibition in malignant CMT-U27 cell line. (C) There was a 50% decrease in GLT25D1 mRNA expression levels after galectin-3 knockdown. cDNA contents were normalized on the basis of predetermined levels of 18S. The results represent the mean ± SD of triplicate samples in one of three similar experiments. *Asterisks indicate significant differences (P < 0.05) by Student's t-test.
nant CMT, we also found a high number of major histocompatibility complex class II positive cells around tumor emboli (data not shown), and its implications for tumor metastasis are currently under investigation.
No matter the mechanisms by which tumor cells enter blood vessels, the presence of cytoplasmic galectin-3 seems to correlate with invasiveness and metastasis. In fact, several in vitro and in vivo studies showed that, when present in the cell cytoplasm, galectin-3 has anti-apoptotic functions (Yoshii et al. 2002; Califice et al. 2004 ). Decreased nuclear expression of galectin-3 has been associated to a more aggressive behavior and poorer prognosis in several studies of different human cancers (Sanjuán et al. 1997; Honjo et al. 2000; Califice et al. 2004) . Accordingly, in malignant CMT, there was a statistically significant loss of galectin-3 nuclear expression when compared with benign tumors. Also, the highly metastatic CMT cell line showed loss of nuclear expression of galectin-3, while the benign cell line, which expressed galectin-3 both in the nucleus and in the cytoplasm, was not able to form tumors after injection into nude mice. Therefore, the subcellular distribution of galectin-3 is an important feature related to malignancy in CMT and may be responsible for increasing apoptosis resistance of tumor cells that migrate and/or are shed into the circulation.
An active mechanism of tumor invasion implies that migratory cells need to invade and degrade ECM in order to intravasate, which requires numerous specific molecular interactions between the tumor cell and the surrounding ECM. It has been reported that galectin-3 is able to promote cell-ECM adhesion by interacting with glycosylated components of ECM such as laminin (Kuwabara and Liu 1996) , elastin (Ochieng et al. 1999 ) and collagen IV (Ochieng et al. 1998) . Therefore, it would be expected that the presence of galectin-3-binding sites in the ECM negatively modulate cell migration. In fact, a decade ago, Choufani et al. (1999) showed that a decreased expression of galectin-3-binding sites was correlated with increased tumor aggressiveness in head and neck squamous cell carcinomas. However, these authors focused only on the expression of galectin-3-binding sites by tumor cells and did not report any alteration in the ECM-binding sites. In our study, we postulate that decreased expression of galectin-3-binding sites in the ECM is critical for metastasis since it allows migratory cancer cells to lose their galectin-3-mediated interaction with glycosylated ECM components. According to the literature, at least two mechanisms could account for the decrease in galectin-3-binding sites in the ECM: (1) increased presence of cleaved galectin-3, which is released into the ECM and could block galectin-3-binding sites (Nangia-Makker et al. 2007 ) and (2) increased sialylation of galectin-3-binding proteins, which could prevent its binding (Zhuo et al. 2008 ). The first suggested mechanism was ruled out by the observation that malignant CMT did not express detectable amounts of stromal galectin-3. Regarding the second mechanism, previous studies of our group using a broad panel of lectins showed increased sialylation in neoplastic cells but not in the ECM of malignant CMT (Pinho et al. 2009 ). Therefore, decreased binding of Gal3/AP to its potential binding sites in the ECM could be related to other glycosylation-related alterations. In fact, by using two plant lectins, we showed that malignant CMT display a reduced availability of terminal galactose residues in the ECM compared with normal tissues. An alternate hypothesis would be that galectin-3-binding sites in the ECM are blocked by the presence of other endogenous galectins. In this regard, we assessed the expression levels of galectin-1, another member of the galectin family of glycan-binding proteins whose expression in malignant tissues has been reported in several tumors, including breast (Jung et al. 2007 ). Interestingly, galectin-1 also plays an important role in tumor progression by promoting cell-cell and cell-ECM adhesion, thus influencing cancer cell invasion and metastasis (Hughes 2001) . The fact that downregulation of galectin-3-binding sites correlated with an upregulation of galectin-1 in the ECM of malignant CMT led us to propose that stroma-associated galectin-1 may partially block galectin-3-binding sites in the ECM. Consistent with this hypothesis, Jung et al. (2007) observed an upregulation of galectin-1 in breast carcinoma tissues and demonstrated that its expression by cancer-associated stromal cells correlated with tumor invasiveness and metastasis. Most recently, Gromov et al. (2010) reported that galectin-1 is upregulated in tumor interstitial fluids of breast cancer patients. Despite the upregulation of galectin-1 in tumor stroma, the hypothesis that other galectin family members may block galectin-3-binding sites in the ECM cannot be ruled out.
Another attractive possibility is that decreased galectin-3-binding sites could be due to altered ECM glycosylation. Since collagen glycosylation affects melanoma cell adhesion to and spreading on collagen IV (Lauer-Fields et al. 2003) , we checked the mRNA expression levels of GLT25D1, a recently identified glycosyltranferase responsible for collagen glycosylation (Schegg et al. 2009 ). GLT25D1 catalyzes the addition of the monosaccharide Gal (β1-O) to hydroxylysine residues in various types of collagen and has not been evaluated in tumor samples or cancer cells before. However, even though decreased expression of GLT25D1 might affect galectin-3-binding sites by reducing collagen galactosylation, we were not able to affirm that galectin-3 or galectin-1 binds this glycan structure found on collagen. In fact, Ahmed et al. (1991) concluded that Gal (β1-O) hydroxylysine residues prepared from natural sponges are unlikely to play a significant role in anchoring galectin-1 to the ECM. However, this question requires further clarification and also new binding studies using other galectins and purified collagen from normal and tumor tissues. Independent of whether or not galectins bind to collagen, the concurrent loss of nuclear galectin-3, and GLT25D1 mRNA expression in malignant CMT argues in favor of a role for nuclear galectin-3 in GLT25D1 gene transcription. However, whether GLT25D1 gene transcription is regulated by nuclear galectin-3 through a similar mechanism described for cyclin D1 (Lin et al. 2002) or GLT25D1 downregulation is linked to epigenetic factors (e.g., promoter methylation), these are questions that remain to be answered.
Altogether, the results presented in this study led us to propose a model in which we correlate the loss and gain of both galectin-3 and galectin-3-binding sites within tumor microenvironment as well as its consequences for tumor metastasis (Figure 9 ). This model, although it emphasizes that loss of galectin-3 expression is important for cell proliferation and tumor progression, underscores the need for novel inhibitors of galectin-3 function as therapeutic agents to reduce tumor metastasis.
Materials and methods

Human tissue
Samples of invasive human breast carcinoma from the files of the Department of Pathology of ICBAS-UP were used in this study in order to compare with the canine samples. After dehydration and paraffin wax embedment, sections of 4 μm were cut and used for immunohistochemistry.
Animal tissues and dogs
A series of 82 spontaneous canine mammary tumors were obtained from bitches submitted to surgery at the Small Animal Clinic of ICBAS-UP with curative intents. The average age of the 82 animals was 10 years old (range 3 to 16 years). Four samples of normal mammary gland tissues from the files of the Department of Pathology of ICBAS-UP were also used in this study. The specimens were fixed in 10% neutral buffered formalin. After dehydration and paraffin wax embedment, sections of 4 μm were cut from each representative paraffin block for staining with hematoxylin and eosin and for immunohistochemistry. Animals were evaluated every 3 months (thorough physical examination, three-view thoracic radiographies, and abdominal ultrasound) during a follow-up postoperative period of 2 years. All dogs were followed until death or until the end of the pre-established observation period.
Animals that died were submitted to complete necropsy and histological confirmation of local recurrences or metastases.
From the initial 41 series of malignant CMT, nine female dogs bared metastatic tumors confirmed by histopathology. Nineteen metastatic lesions of different sites, from seven out of nine dogs, were used in this study.
Cell lines and culture conditions
In this study, we used two different cell lines: (1) a benign CMA07 cell line, established at our laboratory from a primary complex adenoma excised from a 6-year-old female dog, which has undergone more than 50 passages and does not form tumors upon subcutaneous injection into nude mice (unpublished data) and (2) a highly metastatic CMT cell line (CMT-U27) kindly provided by Professor Eva Hellmen from Sweden (Hellmén 1992) . Both cell lines were cultured at 37°C in a humidified 5% CO 2 incubator and maintained in RPMI 1640 medium (with Glutamax and 25 mM Hepes) supplemented with 10% fetal bovine serum and gentamicin (50 μg/mL).
Experimental nude mice
Five 6-week-old female N:NIH(s)II-nu/nu mice were inoculated in the mammary fat pad with a suspension of 10 6 cells of CMT-U27 cell line. Once the xenografted primary tumor at- Fig. 9 . Proposed model to summarize the role of galectin-3 in tumor progression and metastasis. In benign tumors, the increased availability of galectin-3 and galectin-3-binding sites favor galectin-3-mediated cell-cell and cell-ECM interactions, preventing the separation of individual tumor cells and migration through ECM. In malignant tumors, downregulation of galectin-3 and galectin-3-binding sites in the ECM lead to a decreased adhesiveness of galectin-3-expressing tumor cells and facilitate their movement through ECM. Altered ECM glycosylation and blockade of galectin-3-binding sites by other endogenous galectins (e.g., galectin-1) are two factors that may account for the reduction in galectin-3-binding sites availability. After intravasation, galectin-3-expressing tumor cells are able to form homotypic cell aggregates supporting metastatic cell arrest in microcirculation. Also, by promoting interaction between tumor and endothelium cells (heterotypic interactions), galectin-3 facilitates tumor cell extravasation through vascular endothelium. Once in a target organ, galectin-3-expressing tumor cells are able to adhere to the normally glycosylated ECM (which possess plenty of galectin-3-binding sites), thus forming a metastasis or a secondary tumor. Then, the majority of the tumor cells will gradually downregulate or lose expression of galectin-3 in order to proceed further in the transformation pathway.
tained the volume of 1 cm 3 , it was excised under general anesthesia. The animals were humanely euthanized whenever their body weight started to decrease or any signs of poor body condition were shown, and target organs were collected in order to search for distant metastases.
Immunohistochemistry
Expression of Galectin-3 was evaluated in the formalin-fixed, paraffin-embedded sections of both spontaneously occurring CMT and malignant CMT-U27 xenografts, using standard immunohistochemistry protocols. Briefly, 4-μm-thick paraffin sections were deparaffinised, then hydrated, and H 2 O 2 was used to block endogenous peroxidase activity. After blocking with the appropriate normal sera, sections were incubated with the primary antibodies: anti-galectin-3 mAb (M3/38) (Ho and Springer 1982) , which recognizes the N-terminal portion of the protein; chicken anti-galectin-3 polyclonal antibody; anti-E-cadherin clone 4A2C7, (Zymed); anti beta-catenin clone CAT-5H10 (Zymed); and rabbit anti-galectin-1 polyclonal antibody (a kind gift of Dr. Marcelo Dias-Baruffi, University of Sao Paulo, Brazil), overnight at 4°C. This was followed by incubation with the appropriate conjugated secondary antibodies. In order to characterize the glycosylation profile between the normal adjacent and the malignant tissue, 10 cases of malignant CMT of different histological subtypes were incubated with the biotinylated lectins, E. crista-galli (Vector) and peanut lectin (Sigma), for 1 h. This was followed by incubation with the appropriate conjugated secondary antibodies or with the avidin-biotin-peroxidase complex (Vector Laboratories) for 30 min. Peroxidase activity was examined using diaminobenzidine tetrahydroxychloride solution (DAB, Dako) as the substrate. Sections were counterstained with hematoxylin. Negative controls in which the primary antibody was replaced by bovine serum albumin (BSA) 5% in phosphate-buffered saline (PBS) were performed in all series, and sections of human thyroid carcinomas were used as positive controls. The assessment of galectin-3 expression in CMT was based on a semiquantitative analysis, and tumors were grouped, according to the percentage of immunoreactive cells throughout the whole lesion, into: <10%, which was considered negative; <25%; 25-50%; 50-75%, or >75%. Galectin-3-binding sites were detected using a Gal3/AP probe in the same sections (de Melo et al. 2007 ). Sections were incubated with dilution of the probe for 2 h at room temperature. Alkaline phosphatase activity was observed using Fast Red (Dako). Sections were counterstained with hematoxylin. The tissues were classified into 1+ (weak), 2+ (moderate), or 3+ (strong) score of staining intensity. As a negative control, an assay using lactose to inhibit the carbohydrate recognition domain of galectin-3 was performed.
RNA interference
The establishment of galectin-3 knockdown cells was done using a retroviral expression system with short hairpin RNAs as described previously (Friedrichs et al. 2007) . Briefly, the targeting and control vectors were transfected into PhoenixGP packaging cell line, and transfected cells were selected using Puromycin (Sigma). Stable transfectants were seeded (1 × 10 6 cells) and incubated for 24 h at 32°C. The virus-containing media were then collected, filtered through a 0.45-μm filter to remove remnant cells, and used to infect malignant CMT-U27. Six and 12 h postinfection, the media were replaced by selective puromycin-containing media to select infected cells.
RNA extraction and real-time polymerase chain reaction Two canine normal mammary glands and four benign and four malignant CMT were collected and freshly frozen in liquid nitrogen at the local city kennel. A section of each of the 10 cases was included in paraffin and histologically classified. Total RNA was isolated from the CMT cell lines and from freshly frozen mammary benign and malignant CMT using TRI Reagent (Sigma) according to manufacturer's instructions. Briefly, 1 μg of RNA were primed with random hexamers and reverse transcribed using Superscript II (Invitrogen) in a final volume of 20 μL. Two microliters of a 1:10 dilution of this mixture was amplified with SYBR Green (Applied Biosystems) and primers at a final concentration of 300 nM each in a fluorescence reader ABI Prism 7000, and duplicates were run for each reverse transcription product. The level of 18S and GAPDH RNA in each sample was measured and used for normalization of target gene abundance. The primer sequences are listed below.
GAL3: (5′CAGGCAGCTTTTCCATTCGA3′/5′ACTG-CAA CAAATGGGCATCA3′); GLT25D1: (5′CTGAGAACAAGACGGTGGTGG3′/5′ AGGTGTGCGCTTGTAGTAGCC3′)
Immunofluorescence
In order to investigate the galectin-3 subcellular distribution, cells were grown for 24 h on cover glasses pre-coated for 3 h with RPMI 1640 medium supplemented with 10% fetal bovine serum. The cells were then fixed for 10 min in ice-cold methanol and blocked with non-immune donkey serum diluted in 10% BSA for 20 min. Normal serum was replaced with anti-gal-3 monoclonal antibody (M3/38) (Ho and Springer 1982) diluted in 5% BSA, and the cell monolayer was incubated for 1 h. After three washes with 1 × PBS, cells were incubated with fluorescein isothiocyanate (FITC)-labeled secondary antibody (JacksonImmuno Research) diluted in 5% BSA for 30 min in the dark at room temperature, followed by incubation with DAPI (Pierce) in PBS and then mounted in vectashield (Vector). Cells were analyzed with a Leica DMIRE2 fluorescent microscope.
Flow cytometry
For flow cytometry, single-cell suspensions were prepared from CMT-U27 and CMA07 cell lines. Briefly, adherent cells were detached from the flask with trypsin. Subsequently, trypsinized cells were washed and resuspended in PBS supplemented with 10 mM of sodium azide and 1% BSA. The rat anti-galectin-3 antibody (M3/38) (Ho and Springer 1982) and FITC donkey anti-rat (JacksonImmuno Research) were used as primary and secondary antibodies, respectively. For assessing galectin-3-binding sites, cells were incubated with FITC-labeled recombinant galectin-3 in the presence or absence of lactose. Flow cytometric analysis was performed on FACScan (Becton Dickinson, San Jose, CA, USA) using CellQuest software (Becton Dickinson). 
